ImmunityBio
IBRX
IBRX
385 hedge funds and large institutions have $1.36B invested in ImmunityBio in 2026 Q1 according to their latest regulatory filings, with 146 funds opening new positions, 136 increasing their positions, 60 reducing their positions, and 31 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding in top 10
Funds holding in top 10: →
43% more call options, than puts
Call options by funds: $165M | Put options by funds: $115M
39% more funds holding
Funds holding: 276 → 385 (+109)
0.11% more ownership
Funds ownership: 17.2% → 17.31% (+0.11%)
Holders
385
Holding in Top 10
2
Calls
$165M
Puts
$115M
Top Buyers
| 1 | +$86.1M | |
| 2 | +$26.9M | |
| 3 | +$20M | |
| 4 |
PAG
Private Advisor Group
Morristown,
New Jersey
|
+$10.2M |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$9.62M |
Top Sellers
| 1 | -$92.6M | |
| 2 | -$20.4M | |
| 3 | -$20M | |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$16.9M |
| 5 |
Morgan Stanley
New York
|
-$7.44M |
